ImmunOs Therapeutics AG

1 clinical trials · Sponsor

Record	Firm	Date
A Clinical Study to Evaluate the Safety, Tolerability and Efficacy of IOS-1002 Administered Alone and in Combination With Pembrolizumab, a PD-1 Monoclonal Antibody in Advanced Solid Tumors (NCT05763004)	ImmunOs Therapeutics AG	2023-03-15

Every clearance here is in the API, with alerts when new ones post.